Contact
searchSearch
HMP Global
Login
Jennifer Brown, MD, PhD
Videos
Bruton's Tyrosine Kinase Inhibitor Resistance and Treatment Sequencing in Chronic Lymphocytic Leukemia
04/13/2026
Jennifer Brown, MD, PhD
Jennifer Brown, MD, PhD, discusses mechanisms of resistance to BTKi in chronic lymphocytic leukemia, including mutations associated with both covalent and non-covalent agents.
Jennifer Brown, MD, PhD, discusses mechanisms of resistance to BTKi in chronic lymphocytic leukemia, including mutations associated with both covalent and non-covalent agents.
Jennifer Brown, MD, PhD,...
04/13/2026
Oncology
Victor Jimenez Zepeda, MD
Videos
Advances for Patients With High-Risk Smoldering Multiple Myeloma
04/10/2026
Victor H. Jimenez Zepeda, MD
Victor Jimenez Zepeda, MD, discusses the evolving management of patients with high-risk smoldering multiple myeloma.
Victor Jimenez Zepeda, MD, discusses the evolving management of patients with high-risk smoldering multiple myeloma.
Victor Jimenez Zepeda, MD,...
04/10/2026
Oncology
Erin Mulvey, MD
Videos
Advances in Targeted and Immunotherapy for Richter Transformation
04/10/2026
Erin Mulvey, MD
At the 2026 LL&M Winter Symposium, Erin Mulvey, MD, discusses the evolving treatment landscape for Richter transformation.
At the 2026 LL&M Winter Symposium, Erin Mulvey, MD, discusses the evolving treatment landscape for Richter transformation.
At the 2026 LL&M Winter...
04/10/2026
Oncology
Catherine Diefenbach, MD
Videos
New Advances Continue to Improve Outcomes in Hodgkin Lymphoma
04/10/2026
Catherine Diefenbach, MD
At the 2026 LL&M Winter Symposium in Amelia Island, Florida, Catherine Diefenbach, MD, discusses key updates in Hodgkin lymphoma, as presented at ASH 2025.
At the 2026 LL&M Winter Symposium in Amelia Island, Florida, Catherine Diefenbach, MD, discusses key updates in Hodgkin lymphoma, as presented at ASH 2025.
At the 2026 LL&M Winter...
04/10/2026
Oncology
Ajay Nooka, MD
Videos
Bispecific and Cellular Therapies to Transform Multiple Myeloma Treatment
04/02/2026
Ajay K. Nooka, MD, MPH
Ajay Nooka, MD, discusses practice-changing advances in multiple myeloma emerging from 2025 data.
Ajay Nooka, MD, discusses practice-changing advances in multiple myeloma emerging from 2025 data.
Ajay Nooka, MD, discusses...
04/02/2026
Oncology
John Leonard, MD
Videos
Expanding Treatment Options in Mantle Cell Lymphoma
04/02/2026
John P. Leonard, MD
John Leonard, MD, explores recent advances in mantle cell lymphoma.
John Leonard, MD, explores recent advances in mantle cell lymphoma.
John Leonard, MD, explores...
04/02/2026
Oncology
Sarah Rutherford, MD
Videos
Emerging Strategies to Reshape Frontline Treatment of Diffuse Large B-Cell Lymphoma
04/01/2026
Sarah Rutherford, MD
Sarah Rutherford, MD, discusses recent advances in frontline treatment of diffuse large B-cell lymphoma and how emerging data are reshaping clinical practice.
Sarah Rutherford, MD, discusses recent advances in frontline treatment of diffuse large B-cell lymphoma and how emerging data are reshaping clinical practice.
Sarah Rutherford, MD, discusses...
04/01/2026
Oncology
Lindsay Rein, MD
Videos
Emerging Therapeutic Strategies Across Myeloproliferative Neoplasms
04/01/2026
Lindsay Rein, MD
Lindsay Rein, MD, discusses emerging therapeutic strategies across myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia, and myelofibrosis.
Lindsay Rein, MD, discusses emerging therapeutic strategies across myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia, and myelofibrosis.
Lindsay Rein, MD, discusses...
04/01/2026
Oncology
Asher Chanan-Khan, MD
Videos
Emerging Therapies Transform Waldenström Macroglobulinemia
04/01/2026
Asher Chanan-Khan, MD
Asher Chanan-Khan, MD, discusses recent advances in Waldenström’s macroglobulinemia including developments in BTK inhibitors, BCL2 combinations, and novel targeted therapies.
Asher Chanan-Khan, MD, discusses recent advances in Waldenström’s macroglobulinemia including developments in BTK inhibitors, BCL2 combinations, and novel targeted therapies.
Asher Chanan-Khan, MD, discusses...
04/01/2026
Oncology
Mateo Mejia Saldarriaga, MD
Videos
Advancing Treatment for High-Risk Multiple Myeloma Subtypes
04/01/2026
Mateo Mejia Saldarriaga, MD
Mateo Mejia Saldarriaga, MD, discusses the unmet need in high-risk multiple myeloma, including extramedullary disease, CNS involvement, and plasma cell leukemia.
Mateo Mejia Saldarriaga, MD, discusses the unmet need in high-risk multiple myeloma, including extramedullary disease, CNS involvement, and plasma cell leukemia.
Mateo Mejia Saldarriaga, MD,...
04/01/2026
Oncology
Rachid Baz, MD
Videos
BCMA-Targeted Bispecifics and CAR-T in Frontline Multiple Myeloma
03/31/2026
Rachid Baz, MD
Rachid Baz, MD, discusses the emerging role of BCMA-targeted bispecific antibodies and CAR T-cell therapy in transplant-ineligible patients with newly diagnosed multiple myeloma.
Rachid Baz, MD, discusses the emerging role of BCMA-targeted bispecific antibodies and CAR T-cell therapy in transplant-ineligible patients with newly diagnosed multiple myeloma.
Rachid Baz, MD, discusses the...
03/31/2026
Oncology
Ivan Borrello, MD
Videos
Immunotherapy Improves Outcomes in Triple Exposed Multiple Myeloma
03/31/2026
Ivan Borrello, MD
Ivan Borrello, MD, discusses emerging therapies for patients with triple-exposed multiple myeloma.
Ivan Borrello, MD, discusses emerging therapies for patients with triple-exposed multiple myeloma.
Ivan Borrello, MD, discusses...
03/31/2026
Oncology
Gail Roboz, MD
Videos
Targeted Triplet Induction Regimens in Acute Myeloid Leukemia
03/31/2026
Gail J. Roboz, MD
Gail Roboz, MD, discusses emerging strategies in acute myeloid leukemia treatment.
Gail Roboz, MD, discusses emerging strategies in acute myeloid leukemia treatment.
Gail Roboz, MD, discusses...
03/31/2026
Oncology
James Foran, MD
Videos
Molecular Risk Stratification and Treatment Optimization in Acute Lymphoblastic Leukemia
03/31/2026
James Foran, MD
James Foran, MD, provides an update on the evolving treatment landscape for adult patients with acute lymphoblastic leukemia.
James Foran, MD, provides an update on the evolving treatment landscape for adult patients with acute lymphoblastic leukemia.
James Foran, MD, provides an...
03/31/2026
Oncology
Jeffrey Lancet, MD
Videos
Optimizing Decision-Making on Transplantation for Patients With AML
03/31/2026
Jeffrey Lancet, MD
At the 2026 LL&M Winter Symposium, Jeffrey Lancet, MD, discussed the latest clinical insights into determining which patients with acute myeloid leukemia should be recommended for transplant.
At the 2026 LL&M Winter Symposium, Jeffrey Lancet, MD, discussed the latest clinical insights into determining which patients with acute myeloid leukemia should be recommended for transplant.
At the 2026 LL&M Winter...
03/31/2026
Oncology
Kenneth Shain, MD, PhD
Videos
Transplant vs CAR-T Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma
03/31/2026
Kenneth H. Shain, MD, PhD
At the 2026 LL&M Winter Symposium, Kenneth Shain, MD, PhD, explores transplant versus CAR-T therapy in the context of newly diagnosed transplant-eligible patients with multiple myeloma.
At the 2026 LL&M Winter Symposium, Kenneth Shain, MD, PhD, explores transplant versus CAR-T therapy in the context of newly diagnosed transplant-eligible patients with multiple myeloma.
At the 2026 LL&M Winter...
03/31/2026
Oncology
Julio Chavez, MD
Videos
Evolving Treatment Strategies for Patients With Relapsed or Refractory DLBCL
03/19/2026
Julio Chavez, MD
Julio Chavez, MD, reviews current and emerging treatment options for patients with relapsed/refractory diffuse large B-cell lymphoma.
Julio Chavez, MD, reviews current and emerging treatment options for patients with relapsed/refractory diffuse large B-cell lymphoma.
Julio Chavez, MD, reviews...
03/19/2026
Oncology
Richard Furman, MD
Videos
Immature Data Limit Conclusions on Continuous vs Fixed-Duration Frontline CLL Therapies
03/19/2026
Richard Furman, MD
Richard Furman, MD, discusses early results from the CLL-17 trial, underscoring the need for longer follow-up before defining optimal frontline strategies for treatment-naïve patients with chronic lymphocytic leukemia.
Richard Furman, MD, discusses early results from the CLL-17 trial, underscoring the need for longer follow-up before defining optimal frontline strategies for treatment-naïve patients with chronic lymphocytic leukemia.
Richard Furman, MD, discusses...
03/19/2026
Oncology
Jacqueline Barrientos, MD, MS
Videos
Latest Insights Into Marginal Zone Lymphoma Management and Treatment
03/17/2026
Jacqueline Barrientos
At the 2026 LL&M Winter Symposium, Jacqueline Barrientos, MD, MS, presented on current treatment strategies and novel clinical insights in marginal zone lymphoma.
At the 2026 LL&M Winter Symposium, Jacqueline Barrientos, MD, MS, presented on current treatment strategies and novel clinical insights in marginal zone lymphoma.
At the 2026 LL&M Winter...
03/17/2026
Oncology
Alexander E Perl, MD, MS
Videos
Evaluating the 7+3 Regimen in Frontline Acute Myeloid Leukemia Treatment
03/17/2026
Alexander E. Perl, MD
At the 2026 LL&M Winter Symposium, Alexander E Perl, MD, MS, presented the latest evolving data on the commonly utilized 7+3 regimen for patients with newly diagnosed acute myeloid leukemia.
At the 2026 LL&M Winter Symposium, Alexander E Perl, MD, MS, presented the latest evolving data on the commonly utilized 7+3 regimen for patients with newly diagnosed acute myeloid leukemia.
At the 2026 LL&M Winter...
03/17/2026
Oncology
Christopher Hourigan, MD, PhD
Videos
The Expanding Role of Minimal Residual Disease Testing in Acute Myeloid Leukemia
03/13/2026
Christopher Hourigan, DM, DPhil, FRCP
Christopher Hourigan, MD, PhD, reviews the most recent high-impact developments in measurable residual disease (MRD) testing in acute myeloid leukemia, focusing on key updates from recent months.
Christopher Hourigan, MD, PhD, reviews the most recent high-impact developments in measurable residual disease (MRD) testing in acute myeloid leukemia, focusing on key updates from recent months.
Christopher Hourigan, MD, PhD,...
03/13/2026
Oncology
Nina Wagner-Johnston, MD
Videos
Advances in Follicular Lymphoma: Long-Term Outcomes, CAR-T Durability, and Emerging Treatment Strategies
03/13/2026
Nina Wagner Johnston, MD
Nina Wagner-Johnston, MD, highlights excellent long-term outcomes in follicular lymphoma, including 18-year survival data from the University of Iowa/Mayo Clinic SPORE resource, durable CAR-T responses, and promising frontline and relapsed...
Nina Wagner-Johnston, MD, highlights excellent long-term outcomes in follicular lymphoma, including 18-year survival data from the University of Iowa/Mayo Clinic SPORE resource, durable CAR-T responses, and promising frontline and relapsed...
Nina Wagner-Johnston, MD,...
03/13/2026
Oncology
Nilanjan Ghosh, MD, PhD
Videos
Advancements in Treatment Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
04/09/2025
Nilanjan Ghosh, MD, PhD
Nilanjan Ghosh, MD, PhD, FACP discusses new updates in treatment strategies for patients with relapsed/refractory diffuse large B-cell lymphoma including bispecific antibodies and CAR T-cell therapy.
Nilanjan Ghosh, MD, PhD, FACP discusses new updates in treatment strategies for patients with relapsed/refractory diffuse large B-cell lymphoma including bispecific antibodies and CAR T-cell therapy.
Nilanjan Ghosh, MD, PhD, FACP...
04/09/2025
Oncology
C. Ola Landgren, MD, PhD
Videos
Updates in Frontline Therapies for Patients With Transplant-Ineligible Multiple Myeloma
03/21/2025
C. Ola Landgren, MD, PhD shares updates on improvements in cancer outcomes, including prolonged survival and tolerability, for patients with newly diagnosed multiple myeloma who are transplant-ineligible.
C. Ola Landgren, MD, PhD shares updates on improvements in cancer outcomes, including prolonged survival and tolerability, for patients with newly diagnosed multiple myeloma who are transplant-ineligible.
C. Ola Landgren, MD, PhD shares...
03/21/2025
Oncology
Michael Green, PhD
Conference Coverage
Potential Impact of Classification of R/R Diffuse Large B-Cell Lymphoma Microenvironment Archetypes on Patient Treatment and Outcomes
03/17/2025
Michael Green, PhD, discusses relapsed/refractory diffuse large B-cell lymphoma microenvironment archetypes and the effect of immunomodulatory and cellular therapies on patient outcomes.
Michael Green, PhD, discusses relapsed/refractory diffuse large B-cell lymphoma microenvironment archetypes and the effect of immunomodulatory and cellular therapies on patient outcomes.
Michael Green, PhD, discusses...
03/17/2025
Oncology
Rami Komrokji, MD
Conference Coverage
Risk Stratification and Treatment Strategies for High-Risk Myelodysplastic Syndromes
03/05/2025
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Rami Komrokji, MD discusses the latest updates in risk classification, standard of care, and treatment strategies for myelodysplastic syndromes.
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Rami Komrokji, MD discusses the latest updates in risk classification, standard of care, and treatment strategies for myelodysplastic syndromes.
At the 2025 Lymphoma, Leukemia &...
03/05/2025
Oncology
Izidore Lossos, MD
Conference Coverage
Recent Advancements in Treatment of Mantle Cell Lymphoma and Marginal Zone Lymphoma
03/05/2025
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Izidore Lossos, MD shares insights into treatment strategies for patients with mantle cell lymphoma and marginal zone lymphoma.
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Izidore Lossos, MD shares insights into treatment strategies for patients with mantle cell lymphoma and marginal zone lymphoma.
At the 2025 Lymphoma, Leukemia &...
03/05/2025
Oncology
Craig Moskowitz, MD
Conference Coverage
Updates in Standard of Care and Disease Management Strategies for Patients With Hodgkin Lymphoma
03/05/2025
Craig Moskowitz, MD discusses updates in the treatment and management of Hodgkin lymphoma for patients in various disease stages at the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium.
Craig Moskowitz, MD discusses updates in the treatment and management of Hodgkin lymphoma for patients in various disease stages at the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium.
Craig Moskowitz, MD discusses...
03/05/2025
Oncology
Joanna Rhodes, MD, MSCE
Videos
Recent Advancements in Frontline Therapy for Patients with R/R Follicular Lymphoma
02/28/2025
Joanna Rhodes, MD, MSCE discusses advances in frontline treatment, including bispecific antibodies and T-cell therapies, for patients with follicular lymphoma at the 20205 Lymphoma, Leukemia & Myeloma Winter Symposium.
Joanna Rhodes, MD, MSCE discusses advances in frontline treatment, including bispecific antibodies and T-cell therapies, for patients with follicular lymphoma at the 20205 Lymphoma, Leukemia & Myeloma Winter Symposium.
Joanna Rhodes, MD, MSCE...
02/28/2025
Oncology
News
GPRC5D-Targeted CAR T-Cell Therapy Demonstrates Efficacy and Safety for Patients With R/R MM
02/24/2025
Emily Estrada
CAR T-Cell therapy targeting GPRC5D was found to be safe and effective for the treatment of relapsed/refractory multiple myeloma, according to a recent systematic meta-analysis.
CAR T-Cell therapy targeting GPRC5D was found to be safe and effective for the treatment of relapsed/refractory multiple myeloma, according to a recent systematic meta-analysis.
CAR T-Cell therapy targeting...
02/24/2025
Oncology
Fadi Haddad, MD
Videos
Latest Strategies for Treating Patients With Chronic Myeloid Leukemia
02/24/2025
Fadi Haddad, MD, shares the most recent updates in the treatment of patients with chronic myeloid leukemia at the 2025 LL&M Winter Symposium in Miami, Florida.
Fadi Haddad, MD, shares the most recent updates in the treatment of patients with chronic myeloid leukemia at the 2025 LL&M Winter Symposium in Miami, Florida.
Fadi Haddad, MD, shares the most...
02/24/2025
Oncology
John Allan, MD
Videos
Novel Targeted Therapies for Patients With Chronic Lymphocytic Leukemia
02/24/2025
John Allan, MD discusses new approaches for chronic lymphocytic leukemia, including CAR T-cell therapies, bispecific antibodies, and BTK degraders, at the 2025 LL&M Winter Symposium.
John Allan, MD discusses new approaches for chronic lymphocytic leukemia, including CAR T-cell therapies, bispecific antibodies, and BTK degraders, at the 2025 LL&M Winter Symposium.
John Allan, MD discusses new...
02/24/2025
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use